Retapamulin

Drug Profile

Retapamulin

Alternative Names: '833; 275833; 275833AA; Altabax; ALTARGO; SB 275833

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Antibacterials; Heterocyclic bicyclo compounds; Skin disorder therapies; Small molecules
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gram-positive infections; Impetigo; Skin and soft tissue infections
  • Discontinued Sinusitis

Most Recent Events

  • 30 Nov 2015 Retapamulin licensed to Aqua Pharmaceuticals for commercialisation in USA
  • 23 Nov 2015 Retapamulin licensed to Almirall in USA
  • 31 May 2014 GlaxoSmithKline completes a phase I feasibility trial in Healthy volunteers in USA (NCT01812382)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top